2019 Global Cardio-Oncology Summit Proceedings

This State of the Art Review, Proceedings From the Global Cardio-Oncology Summit (GCOS) by D. Lenihan, L. Hajjar, et al., features the following videos that were recorded onsite at the GCOS meeting in Brazil. These videos succinctly summarize the priorities for the field of CardioOncology as discussed at the GCOS meeting and as detailed in the Review.

 
  • Introduction
    Drs. Daniel Lenihan and Ludhmila Hajjar
     

    The discipline of cardio-oncology has expanded at a remarkable pace. Recent developments and challenges to clinicians who practice cardio-oncology were presented at the Global Cardio-Oncology Summit on October 3 to 4, 2019, in São Paulo, Brazil.

  • Defining Robust Predictors of Cardiotoxicity
    Drs. Daniela Cardinale and Anne Blaes
     

    Highlights recent developments for the use of cardiac biomarkers and novel imaging tools to assist in detection of cardiotoxicity, optimal timing and performance of multimodality imaging to support cardiac safety, and best practice strategies for the prevention of cardiac dysfunction.

  • Clarifying the Role of Cardioprotection
    Drs. Christine Brezden-Masley and Susan Dent
     

    Describes the choices of potentially cardiotoxic therapy and the impact on cancer outcomes of contemporary treatment options (using breast cancer as an example) while balancing the known risks for toxicity in prescribing paradigms. Discusses advances in our understanding of the modifications to usual patterns of treatment to be best tailored for an individual.

  • Managing and Preventing Thromboembolic Events in Patients With Cancer
    Drs. Chiara Melloni and Joerg Herrmann
     

    Describes the current data regarding treatment strategies for identified thrombotic complications in the era of novel anticoagulants. Details advances in the strategies for the treatment of vasospasm, endothelial dysfunction, and vascular over-reactivity.

  • Improving CV Outcomes in Stem Cell Transplantation
    Drs. Saro Armenian and Daniel Lenihan
     

    Describes our understanding and advances in the impact of CV disease in the treatment of hematologic malignancy including hematopoietic stem cell transplantation.

  • Personalizing Cardiovascular Interventions
    Drs. Carlos Campos and Anju Nohria
     

    Discusses whether the Society for Thoracic Surgeons (STS) risk score reflect outcomes of TAVR procedures in patients with cancer. Characterizes CAD management in the context of cancer therapy and depicts a meaningful strategy for intervention.

  • Building The Community
    Drs. Alex Lyon and Joerg Herrmann
     

    Outlines what is required for adequate Cardio-Oncology training, as well as considerations from a fellowship training perspective, how to create an effective program for service provision, and connections to international programs.

  • Detecting and Treating Adverse CV Events Associated With Immunotherapy
    Drs. Tom Neilan and Gustavo Fernandes
     

    Details the impact of immunotherapy on cancer outcomes and illuminate the potential cautionary tales of adverse events in the CV system and what we need to do to minimize toxicity.

  • Understanding Multi-Targeted Tyrosine Kinase Inhibitors Cardiotoxicity
    Drs. Mike Fradley and Joerg Herrmann
     

    In every area of cancer treatment, there are specific therapeutic targets. The adverse event profile of any therapy is not well established. As more patients are treated with a developing therapy, it becomes obvious that we need to “keep our eyes wide open” to whatever CV events are possible. Once these are understood, strategies to identify these toxicities as well as optimal treatment strategies need to be devised.

  • Enhancing Survivorship Care
    Drs. Greg Armstrong and Joseph Carver
     

    Describes how we report on important CV findings, how we integrate with primary care providers, and how we treat CV risk factors in this population is essential.

  • Advancing the Field of Cardio-Oncology
    Drs. Bonnie Ky and Daniel Lenihan
     

    To advance the field, the mission needs to be focused on improving the lives of cancer patients and survivors. To accomplish this mission, goals and strategies were proposed in the following 3 domains: research, clinical care, and education. Major goals in each of these domains include advancement of precision medicine; provision of evidence-based patient care focused on improving outcomes; and the generation and dissemination of knowledge to our multidisciplinary community.

Advertisement